One-Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real-World GETAID Study.

ABSTRACT:

Introduction

Upadacitinib (UPA) is effective for treating luminal Crohn's disease (CD), but data on perianal CD (pCD) remain limited.

Methods

All consecutive patients with active pCD (primary and/or secondary lesions) treated with UPA across 13 French centres between September 2022 and August 2025 were included in a retrospective cohort study. Clinical remission was defined as absence of fistula drainage (spontaneous or on gentle pressure) and healing of anal ulcerations without initiation of new therapy. Clinical response was defined as ≥ 50% improvement in fistulas and/or ulcerations based on physician assessment. Clinical outcomes were analysed using non-responder imputation, and magnetic resonance imaging (MRI) outcomes as observed.

Results

Among the 59 patients i

SUBMITTER: Richard N 

PROVIDER: S-EPMC13309209 | biostudies-literature | 2026 Jul

REPOSITORIES: biostudies-literature